Eli Lilly announced it plans to file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027. This update follows successful results from two additional late-stage Phase 3 trials, which demonstrated significant weight loss and improvements in blood sugar control for adults with obesity who also have Type 2 diabetes or cardiovascular disease. Although the company initially aimed to submit an application as early as 2026, it is taking extra time to complete thorough manufacturing and quality-control data verification.

In one of the recent trials, participants with obesity and diabetes experienced an average weight loss of around 20.8%, nearly 50 pounds, over 80 weeks. Another study involving severely obese adults with cardiovascular disease showed an average weight reduction of 22.6%, equating to about 55.8 pounds during the same period. Besides weight loss, the drug also positively impacted cardiovascular risk factors, further underscoring its potential benefits beyond just managing body weight.

Retatrutide is positioned as a key addition to Eli Lilly’s obesity treatment portfolio, which already includes the injection Zepbound and the pill Foundayo. The drug operates by targeting three hormones—GLP-1, GIP, and glucagon—differentiating it from current therapies that affect one or two of these pathways. This triple hormone approach appears to deliver stronger appetite suppression and greater satisfaction for patients, which may translate into more effective weight management compared to competitors like Novo Nordisk’s semaglutide-based Wegovy.

Analysts estimate retatrutide could generate $3.8 billion in sales by 2030, making it critical for Eli Lilly’s efforts to maintain market leadership in the obesity and diabetes arena. This sector is rapidly expanding and is forecasted to be worth around $100 billion by the 2030s. As the drugmaker advances toward regulatory submission, it aims to capitalize on growing demand for innovative weight-loss treatments that address multiple metabolic conditions simultaneously.